Company news

3SBio, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Next Day Disclosure Return

October 14, 2026

Next Day Disclosure Return

October 13, 2026

Next Day Disclosure Return

October 12, 2026

Next Day Disclosure Return

October 9, 2026

Next Day Disclosure Return

October 8, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026

October 2, 2026

2026 Interim Report

September 30, 2026

Next Day Disclosure Return

September 29, 2026

Next Day Disclosure Return

September 28, 2026

3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone

March 31, 2026

2025 Interim Results Presentation

August 31, 2025

2024 ESG Report

April 30, 2025

3SBio Unveils 2024 Annual Results: Profit Surges 34.9% YoY, Innovation Pipeline Delivers Strong Value

March 25, 2025

2025 43rd Annual J.P. Morgan Healthcare Conference Corporate Presentation

January 21, 2025

2024 Interim Report

September 30, 2024

3SBio Unveils 2024 Interim Results: Revenue Up 16% YoY, Autoimmune Pipeline Poised for a Promising Phase

August 21, 2024

3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced

August 24, 2023

2022 ESG Report

April 28, 2023

3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%

March 21, 2023

2022 Interim Results Presentation

August 24, 2022

1530.HK) _ Prospectus

June 24, 2022

2021 ESG Report

May 24, 2022

2021Annual Report

April 29, 2022

3SBio announces 2021 annual results, with net profit attributable to owns of the parents almost doubling under accelerated growth of diversified businesses

March 30, 2022

2021Annual Results

March 28, 2022

Documents on Display

December 21, 2021

3SBio announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development

August 26, 2021

3SBio announces 2020 annual results, tapping integrated platform advantages for steady growth

March 30, 2021

3SBio Inc. received milestone payment of USD 4 million upon commencement of phase III clinical program of SEL-212

November 23, 2020

3SBio Announces Acceptance of IND application for bevacizumab biosimilar in China

September 14, 2020

Voluntary announcement - acceptance of the IND application for bevacizumab biosimilar in Mainland China

September 14, 2020

Decks

The 5 newest of 23 decks. Every deck is listed under its year.